Edoxaban
Brand: Lixiana (EU/JP) / Savaysa (US) / Edoxo (IN) / Edosafe (IN) / Edoxava (BD)
Anticoagulant
NOAC / DOAC (Xa inhibitor)
Pharmacokinetics
| Half-life | 13 hours |
| Tmax | 2 h |
| Bioavailability | 62 % (approx) |
| Protein Binding | 55 % |
| Volume of Distribution | 0.1 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | no |
| Notes | Avoid if CrCl >95 ml/min due to reduced efficacy; reduce dose in renal impairment; minimal drug-drug interactions. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Bleeding (GI > intracranial), anemia, rare hepatic dysfunction
Contraindications:
Active major bleeding, severe hepatic impairment, CrCl <15 or >95 ml/min
Precautions:
Assess renal function before starting; reduced efficacy in hyperfiltration states (CrCl >95); reversal agent = Andexanet alfa (off-label use)